China Shineway Pharmaceutical : TURNOVER FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2019

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2877)

TURNOVER FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2019

The board of directors (the "Board") of China Shineway Pharmaceutical Group Limited (the "Company") is pleased to announce that, the turnover of the Company and its subsidiaries (together, the "Group") for the nine months ended 30 September 2019 based on its management accounts which have not been reviewed by the auditors, reached RMB 2,050 million, representing an increase of 4.6% as compared with the same period of 2018, and in particular:

• Turnover of injection products decreased by 7.1% to RMB 953 million;
• Turnover of soft capsule products increased by 5.7% to RMB 351 million;
• Turnover of granule products decreased by 3.4% to RMB 259 million;
• Turnover of TCM formula granule products increased by 67.6% to RMB 377 million; and
• Turnover of products in other forms increased by 1.9% to RMB 110 million.

In terms of product mix, injection products, soft capsule products, granule products and TCM formula granule products accounted for approximately 46.5%, 17.1%, 12.6% and 18.4% of the total turnover respectively for the nine months ended 30 September 2019.

Shareholders and investors are advised to exercise caution in dealing in the shares of the Company.

By order of the Board

China Shineway Pharmaceutical Group Limited

Li Zhenjiang

Chairman

Hong Kong, 31 October 2019

As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang, Ms. Xin Yunxia, Mr. Li Huimin and Mr. Chen Zhong; and the independent non-executiveDirectors are Ms. Cheng Li, Prof. Luo Guoan and Mr. Cheung Chun Yue Anthony.